NDLI: Animal models in the drug discovery pipeline for Alzheimer's disease

Please wait, while we are loading the content...

Animal models in the drug discovery pipeline for Alzheimer's disease

Content Provider	Scilit
Author	Dam, Debby Van Deyn, Peter Paul De
Copyright Year	2011
Description	Journal: British Journal of Pharmacology With increasing feasibility of predicting conversion of mild cognitive impairment to dementia based on biomarker profiling, the urgent need for efficacious disease-modifying compounds has become even more critical. Despite intensive research, underlying pathophysiological mechanisms remain insufficiently documented for purposeful target discovery. Translational research based on valid animal models may aid in alleviating some of the unmet needs in the current Alzheimer's disease pharmaceutical market, which includes disease-modification, increased efficacy and safety, reduction of the number of treatment unresponsive patients and patient compliance. The development and phenotyping of animal models is indeed essential in Alzheimer's disease-related research as valid models enable the appraisal of early pathological processes - which are often not accessible in patients, and subsequent target discovery and evaluation. This review paper summarizes and critically evaluates currently available animal models, and discusses their value to the Alzheimer drug discovery pipeline. Models dealt with include spontaneous models in various species, including senescence-accelerated mice, chemical and lesion-induced rodent models, and genetically modified models developed in Drosophila melanogaster, Caenorhabditis elegans, Danio rerio and rodents. Although highly valid animal models exist, none of the currently available models recapitulates all aspects of human Alzheimer's disease, and one should always be aware of the potential dangers of uncritical extrapolating from model organisms to a human condition that takes decades to develop and mainly involves higher cognitive functions.
Related Links	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3229762/pdf http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2011.01299.x/pdf
Ending Page	1300
Page Count	16
Starting Page	1285
e-ISSN	14765381
DOI	10.1111/j.1476-5381.2011.01299.x
Journal	British Journal of Pharmacology
Issue Number	4
Volume Number	164
Language	English
Publisher	Wiley-Blackwell
Publisher Date	2011-10-01
Access Restriction	Open
Subject Keyword	Journal: British Journal of Pharmacology Alzheimer's Disease Caenorhabditis Elegans Drosophila Melanogaster Translational Research
Content Type	Text
Resource Type	Article

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

High-throughput screening and small animal models, where are we?

Animal models in the drug discovery pipeline for Alzheimer's disease

Alzheimer's disease drug discovery: in vivo screening using Caenorhabditis elegans as a model for ß-amyloid peptide-induced toxicity.

Animal models in the drug discovery pipeline for Alzheimer's disease.

Fucoxanthin increases lifespan of Drosophila melanogaster and Caenorhabditis elegans.

The Evaluation of Geroprotective Effects of Selected Flavonoids in Drosophila melanogaster and Caenorhabditis elegans

Translational neuropharmacology and the appropriate and effective use of animal models.

Neuroprotective Effects of Oligosaccharides in Rehmanniae Radix on Transgenic Caenorhabditis elegans Models for Alzheimer’s Disease

Using Drosophila melanogaster as a suitable platform for drug discovery from natural products in inflammatory bowel disease

Animal models in the drug discovery pipeline for Alzheimer's disease

Similar Documents

High-throughput screening and small animal models, where are we?

Animal models in the drug discovery pipeline for Alzheimer's disease

Alzheimer's disease drug discovery: in vivo screening using Caenorhabditis elegans as a model for ß-amyloid peptide-induced toxicity.

Animal models in the drug discovery pipeline for Alzheimer's disease.

Fucoxanthin increases lifespan of Drosophila melanogaster and Caenorhabditis elegans.

The Evaluation of Geroprotective Effects of Selected Flavonoids in Drosophila melanogaster and Caenorhabditis elegans

Translational neuropharmacology and the appropriate and effective use of animal models.

Neuroprotective Effects of Oligosaccharides in Rehmanniae Radix on Transgenic Caenorhabditis elegans Models for Alzheimer’s Disease

Using Drosophila melanogaster as a suitable platform for drug discovery from natural products in inflammatory bowel disease

Animal models in the drug discovery pipeline for Alzheimer's disease